CARM vs FATE vs CRSP vs NTLA vs JPM

For growth investors, Carisma Therapeutics, Inc.

(CARM) is the stronger pick with 31. 6% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Fate Therapeutics, Inc. (FATE) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -99. 6% for Carisma Therapeutics, Inc. (CARM). Over 10 years, the gap is even starker: JPM returned +481. 2% versus CARM's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Carisma Therapeutics, Inc.

(CARM) is the lower-risk stock at -0. 80β versus Intellia Therapeutics, Inc. 's 2. 46β — meaning NTLA is approximately -407% more volatile than CARM relative to the S&P 500. On balance sheet safety, Intellia Therapeutics, Inc. (NTLA) carries a lower debt/equity ratio of 14% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Carisma Therapeutics, Inc.

(CARM) is pulling ahead at 31. 6% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Carisma Therapeutics, Inc. grew EPS 43. 6% year-over-year, compared to -49. 1% for CRISPR Therapeutics AG. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — NTLA leads at 76. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 163.

2% to $5. 50.

In this comparison, JPM (1.

8% yield) pays a dividend. CARM, FATE, CRSP, NTLA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Carisma Therapeutics, Inc.

(CARM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 80)). Intellia Therapeutics, Inc. (NTLA) carries a higher beta of 2. 46 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CARM: -99. 1%, NTLA: -43. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CARM (Healthcare) and FATE (Healthcare) and CRSP (Healthcare) and NTLA (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CARM is a small-cap high-growth stock; FATE is a small-cap quality compounder stock; CRSP is a small-cap quality compounder stock; NTLA is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while CARM, FATE, CRSP, NTLA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.